POLB announces today it has been granted a patent by the US Patent and Trademark Office (USPTO) for POLB 001 for the use of certain p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of hypercytokinaemia (or cytokine storm) and severe influenza through the modulation of the immune response (reducing the bodys hyperinflammatory response). The patent also allows for the use in combination with an antiviral agent which broadens the scope and increases the commercial pote ....
08 Mar 2023
POLB 001 IP estate strengthened
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
POLB 001 IP estate strengthened
Poolbeg Pharma PLC (POLB:LON) | 10.2 0 3.0% | Mkt Cap: 51.2m
- Published:
08 Mar 2023 -
Author:
Karl Keegan -
Pages:
3
POLB announces today it has been granted a patent by the US Patent and Trademark Office (USPTO) for POLB 001 for the use of certain p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of hypercytokinaemia (or cytokine storm) and severe influenza through the modulation of the immune response (reducing the bodys hyperinflammatory response). The patent also allows for the use in combination with an antiviral agent which broadens the scope and increases the commercial pote ....